Delapril HCl is a novel and potent inhibitor of ACE (angiotensin-converting enzyme) with the potential to be used for the treatment of cardiovascular diseases.

Physicochemical Properties

Molecular Formula	C26H32N2O5CLH
Molecular Weight	489.009
Exact Mass	488.207
CAS #	83435-67-0
Related CAS #	Delapril-d3 hydrochloride;2714473-25-1;Delapril;83435-66-9
PubChem CID	5362115
Appearance	White to off-white solid powder
Boiling Point	659.7ºC at 760 mmHg
Melting Point	169ºC
Flash Point	352.7ºC
LogP	3.802
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	12
Heavy Atom Count	34
Complexity	649
Defined Atom Stereocenter Count	2
SMILES	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2.Cl
InChi Key	FDJCVHVKXFIEPJ-JCNFZFLDSA-N
InChi Code	InChI=1S/C26H32N2O5.ClH/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22;/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30);1H/t18-,23-;/m0./s1
Chemical Name	2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid;hydrochloride
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	In spontaneously hypertensive rats (SHR), delapril (3 mg/kg; oral administration for 2 weeks) exhibits strong ACE inhibitory activity [1]. In several experimental models of hypertension, dilapril (1–10 mg/kg; oral) significantly and persistently lowers blood pressure [1].
Animal Protocol	Animal/Disease Models: SHR[1] Doses: 3 mg/kg Route of Administration: po (po (oral gavage)) 2 weeks Experimental Results: Effective ACE inhibitory activity. Animal/Disease Models: 2 kidneys, 1 hypertensive rat, dog and SHR[1] Doses: 1-10 mg/kg Route of Administration: Oral Experimental Results:It has significant and lasting antihypertensive effect.
References	[1]. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F.
Additional Infomation	Delapril hydrochloride is a peptide. Delapril Hydrochloride is the hydrochloride salt of delapril, a lipophilic, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, delapril is converted to two active metabolites, delapril diacid and 5-hydroxy delapril diacid, which competitively bind to and inhibit ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Delapril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. See also: Delapril (annotation moved to).

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~511.25 mM) H2O : ~1.72 mg/mL (~3.52 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.0449 mL	10.2247 mL	20.4495 mL
	5 mM	0.4090 mL	2.0449 mL	4.0899 mL
	10 mM	0.2045 mL	1.0225 mL	2.0449 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.